Jump to content
Crime Forum
FORUMS BLOG/NEWS USER BLOGS USER MEDIA ADVERTS   ADD  MANAGE CHAT CLUBS & USER'S PERSONAL FORUMS LINK EXCHANGE

Narender

Members
  • Content Count

    87
  • Joined

  • Last visited

Community Reputation

0 Neutral
  1. Key Inclusions § An overview of the overall landscape of BBB penetration technologies, featuring an in-depth analysis of the technologies based on a number of parameters, such as status of development (developed and under development), affiliated approach, type of compatible pharmacological molecule(s) crossing the BBB (small molecule and biologic), target receptor(s), target disease indication(s), patent availability, and licensing activity. In addition, it presents a detailed assessment of BBB technology developers and analyses based on parameters, such as year of establishment, compan
  2. The concept of BBB penetration is anticipated to bring about a paradigm shift in modern healthcare. In fact, experts believe that there is an important relationship between the recent pandemic of Coronavirus disease (COVID-19) and cerebrovascular system, presenting commercial opportunities for players engaged in the development of BBB penetrating drugs. To order this 400+ page report, which features 145+ figures and 205+ tables, please visit this https://www.rootsanalysis.com/reports/310/request-sample.html The USD 940 million (by 2030) financial opportunity within the
  3. Roots Analysis has done a detailed study on Blood-Brain Barrier (BBB) Market (2nd Edition), 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics, covering key aspects of the industry’s evolution and identifying potential future growth opportunities. To order this 400+ page report, which features 145+ figures and 205+ tables, please visit this https://www.rootsanalysis.com/reports/310/request-sample.html Key Market Insights § More than 110 drugs, capable of penetrating this elusive barrier are currently being evaluated for the treat
  4. Advances in biotechnology have enabled the development of versatile in vitro (static and dynamic), in vivo (micro-dialysis), and in situ (brain perfusion) blood–brain barrier models, allowing more effective and safe delivery of drugs across brain capillaries Roots Analysis is pleased to announce the publication of its recent study, titled, “Blood-Brain Barrier (BBB) Market (2nd Edition), 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics.” The report features an extensive study of the current market landscape, offering an in
  5. Key Inclusions § A detailed review of the overall landscape of bispecific antibody therapeutics, including information on drug developers, phase of development (marketed, clinical, and preclinical / discovery) of the pipeline candidates, target antigen, type of antibody format, mechanism of action, target disease indication(s), therapeutic area, broader disease segment, route of administration, mode of administration and patient segment. § A comprehensive list of novel technology platforms that are either currently available or being developed by various firms for the generation o
  6. With various target combinations and novel mechanisms of action, bispecific antibodies are presently recognized as a potent class of targeted therapies, with the potential to be used as treatment options for a variety of disease indications. Several pipeline candidates have recently entered mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years. To order this 370+ page report, which features 90+ figures and 110+ tables, please visit this https://www.rootsanalysis.com/reports/286/request-sample.html The USD 6.9 bill
  7. Roots Analysis has done a detailed study on Bispecific Antibody Therapeutics Market (4th Edition), 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities. To order this 370+ page report, which features 90+ figures and 110+ tables, please visit this https://www.rootsanalysis.com/reports/286/request-sample.html Key Market Insights § With two approved drugs and close to 300 clinical / preclinical product candidates, the bispecific antibody therapeutics pipeline has evolved significantly over the pas
  8. Bispecific antibody therapeutics represent a transformative approach to modern treatment; over the years, this upcoming class of ‘two-target’ artificially engineered drugs have generated significant enthusiasm within the medical science community Roots Analysis is pleased to announce the publication of its recent study, titled, “Bispecific Antibody Therapeutics Market (4th Edition), 2020-2030.” The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. The study
  9. Key Inclusions § A detailed review of the overall landscape of the biopharmaceutical contract manufacturing market, featuring a comprehensive list of active CMOs and detailed analysis of the manufacturing service providers based on a number of parameters, such as scale of operation (preclinical, clinical and commercial), type of biologics manufactured (peptides / proteins, antibodies, vaccines, cell therapies, gene therapies, antibody drug conjugates, vectors, biosimilars, nucleic acids and others), type of expression systems used (mammalian, microbial and others), year of establishment,
  10. Owing to the ever-increasing number of start-ups that are involved in R&D of novel biologics, there is an enormous opportunity for the CMOs in this domain. It is worth emphasizing that, since 2000, more than 115 new CMOs have been established in order to serve to the growing demand for novel biologics that have specific manufacturing requirements. The contemporary contract services market features a mix of large and small-sized CMOs and is characterized by multiple mergers and acquisitions as stakeholders strive to broaden their respective service portfolios. This has enabled several CMOs
  11. Roots Analysis has done a detailed study on Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities. To order this 750+ page report, which features 200+ figures and 250+ tables, please visit this link Key Market Insights § Over 235 companies worldwide claim to offer contract manufacturing services for various types of biopharmaceutical drug / therapy products. § The market landscape is highly fragmented featuring the presence of both established
  12. Outsourcing has become a popular trend among biopharmaceutical developers, allowing them to leverage the expertise / larger production capacities of CMOs / CDMOs and achieve significant cost and time related advantages Roots Analysis is pleased to announce the publication of its recent study, titled, “Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030.” The report features an extensive study on the contract service providers within the biopharmaceutical industry. The study features in-depth analysis, highlighting the capabilities of a diverse set of bio
  13. Key Inclusions § A detailed assessment of the current market landscape, including information on drug developer(s), phase of development (marketed, clinical and preclinical / discovery stage) of lead candidates, target immune checkpoints, their respective mechanisms of action (inhibitory or stimulatory), type of therapeutic modality used (monoclonal antibody, antibody fragment, small molecule and others), route of administration (intravenous, subcutaneous, oral and others), target disease indication, target therapeutic area and type of therapy (monotherapy, combination therapy and both)
  14. Despite the fact that biopharmaceuticals offer significant profit margins, innovator companies are plagued by high costs of development, complex production protocols and special procedures and equipment for fill / finish operations. Consequently, a number of drug manufacturers have demonstrated a preference for outsourcing fill / finish operations of such products. To order this 480+ page report, which features 350+ figures and 260+ tables, please visit this link The USD 4.2 billion (by 2030) financial opportunity within the biologics fill / finish services market has b
  15. Roots Analysis has done a detailed study on Biologics Fill / Finish Services Market, 2019-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities. To order this 480+ page report, which features 237 figures and 267 tables, please visit this link Key Market Insights § Over 115 companies located in various regions across the globe claim to provide contract fill / finish services for various types of biopharmaceutical drug / therapy products § The market landscape features a mix of both established players an
×
  • Create New...